Citations

Clear

2960 citation(s) found for "Kim, In-Ho".

Albumin Therapy for Advanced Liver Disease: New Data from the EASL Congress 2026
Kim, W. Ray, Pompil, Enrico, Fernández, Javier, Biswas, Sagnik, Sood, Siddharth , Biswas, Sagnik

Mayo Clinic

EMJ Hepatology | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.33590/emjhepatol/1h7598io. Get It

The role of human albumin therapy in the management of advanced liver disease is not yet fully established across all settings and remains a topic of debate. The significant and complicated burden of the disease, coupled with limited therapeutic options, presents ongoing challenges. At the European Association for the Study of the Liver (EASL) Congress 2026, studies in patient populations worldwide delivered new insights to add to the debate on the use of human albumin therapy at the most severe end of the liver disease spectrum. This article reviews a selection of the latest data, evaluating long-term albumin therapy for decompensated cirrhosis, as well as Phase III study evidence on the use of therapeutic plasma exchange (TPE) for acute-on-chronic liver failure (ACLF).
Integration and Long-Term Use of the CorTec-BCI2000 Platform in an In Vivo Canine Model
Lampert, F. , Ayyoubi, Amir Hossein , Besheli, Behrang Fazli , Engelhardt, William , Kim, Inyong , Ince, Nuri F., Brunner, Peter, Worrell, Gregory A., Miller, Kai, Mívalt, Filip , Jensen, Michael A. , Ince, Nuri F. , Brunner, Peter , Worrell, Gregory A. , Miller, Kai J.

Mayo Clinic

2025 12th International IEEE/EMBS Conference on Neural Engineering (NER) | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-6

10.1109/ner61569.2025.11588913 Get It

Sports and Exercise Cardiology: A New Frontier in Cardiovascular Disease Management
Cornwell, William K. , Dineen, Elizabeth H. , Petek, Bradley J. , Shafer, Keri M. , Davenport, Eddie D , Chung, Eugene H. , Kim, Jonathan H. , Levine, Benjamin D. , Davenport, Eddie , Levine, Benjamin D

Mayo Clinic

Circulation: Population Health and Outcomes | July 9, 2026 | Volume: 19 | Issue: 8 | Pages: No page available

10.1161/circoutcomes.126.013583 | PMID 42422937 Get It

Exercise and physical activity are recognized as essential tools to optimize fitness and longevity, improve overall health, and reduce the risk of cardiovascular disease and other major comorbidities. However, there are inherent risks associated with participation in sports and exercise, regardless of the level of competition or skill required. As such, there is a need for cardiologists to understand the unique aspects of competitive and recreational athletics, as well as sport and exercise science, as it relates to overall heart health and cardiovascular risk. In this article, we provide an overview of the essential aspects of sports and exercise cardiology. We describe the roles and responsibilities of a sports and exercise cardiologist as a member of a comprehensive team of experts who provide care of athletes at all levels of sport, emphasize the importance of risk stratification and prevention of sudden cardiac arrest, the role of exercise for maintaining and optimizing overall health in the general population, describe the growing field of sports electrophysiology and also discuss unique aspects of sports cardiology applied to environmental health and care of the tactical athlete. Knowledge gaps and directions for future clinical and research investigation are reviewed.
Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma
Kassamali, Bina , Schoenfeld, Jonathan D., Sethi, Rosh, Bakst, R H, Barker, C. A., Bradford, Carol R., Carr, David R., Chandra, Sunandana , Connolly, Karen L., Demer, Addison M. , Doonan, Bently, Emerick, Kevin, Friedman, Ben J. , Gali, Linna L., Galloway, Thomas J., Geiger, Jessica L., Kohen, Laurie, Koyfman, Shlomo, Kumar, Shweta Sharat, Learned, Kim O. , Leitenberger, Justin J., Lilley, Elizabeth J. , Lukens, John N. , Medina, Theresa , Mitra, Devarati , Ozog, David, Pashtan, Itai, Pham, Nancy , Powers, Molly, Srivastava, Divya, Taylor, Charlotte S., Witek, Matthew E. , Wysong, Ashley, Zander, David, Silk, Ann W., Jambusaria-Pahlajani, Anokhi, Ruiz, Emily S., Chen, Michelle , Kumar, Shweta S. , Schoenfeld, Jonathan D. , Barker, Christopher A. , Bhatt, Alok A. , Bradford, Carol R. , Bunch, Paul M. , Carr, David R., Carucci, John A. , Chen, Michelle , Connolly, Karen , Doonan, Bently P. , Emerick, Kevin S. , Friedman, Ben J. , Galloway, Thomas J. , Guenette, Jeffrey P. , Kelly, Hillary R. , Khushalani, Nikhil I. , Kohen, Laurie Linden, Leitenberger, Justin J. , Medina, Theresa M. , Pashtan, Itai , Patel, Vishal Anil , Srivastava, Divya , Swiecicki, Paul Loren , Wysong, Ashley, Silk, Ann Willman , Jambusaria‐Pahlajani, Anokhi , Ruiz, Emily S.

Mayo Clinic

JAMA Dermatology | July 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamadermatol.2026.2163 | PMID 42418212 Get It

Importance There is no consensus on staging and surveillance imaging for cutaneous squamous cell carcinoma (CSCC). Although imaging has been shown to affect management, broad recommendations from the National Comprehensive Cancer Network have led to variability in clinical practice. Objective To develop multidisciplinary consensus recommendations on the use of staging and surveillance imaging of localized CSCC. Evidence Review A multidisciplinary expert panel across academic and clinical practice settings convened a Delphi consensus, with 3 iterative survey rounds from January to June 2025. Data were analyzed from February 2025 to January 2026. Eligibility defined by at least 1 to 2 CSCC publications during the previous 5 years, involvement in a relevant clinical trial, experience treating at least 3 patients monthly with CSCC, and/or 5 years or longer of clinical practice. Fifty-four experts were invited and 45 (83%) completed all 3 rounds and were included in the final analysis. Structured Delphi surveys evaluated clinical scenarios, imaging modalities, and surveillance strategies for CSCC. Consensus and near-consensus recommendations were generated, defined as 80% or greater and 70% to 79% agreement, respectively. Findings The 45 participants (21 female individuals [47%] and 24 male individuals [53%]; 14 Asian individuals [31%], 1 multiracial individual [2%], and 30 White individuals [67%]) consisted of dermatology (15 [33%]), medical oncology (7 [16%]), radiation oncology (9 [20%]), radiology (9 [20%]), surgery (3 [7%]), and otolaryngology specialists (2 [4%]). The Delphi panel recommended staging and surveillance for CSCCs with at least a 15% risk of metastasis. Consensus or near consensus was reached to recommend staging and surveillance imaging for tumors with a concern for metastasis, bone invasion, invasion beyond subcutaneous fat, large-caliber nerve invasion, or a diameter of 4 cm or larger or the combination of tumors with poorly differentiated histology and any of the following: diameter of 2 cm or larger, lymphovascular invasion and subcutaneous fat invasion, or lymphovascular invasion and small-caliber perineural invasion. Computed tomography imaging was the preferred modality for nodal staging (38 [84%]) and surveillance (35 [78%]). For surveillance duration, consensus was reached to provide imaging for at least 2 years, and near consensus was reached for at least 3 years. Conclusions and Relevance This study provides an expert consensus–based framework to standardize imaging in localized CSCC that may inform future guidelines.
Intraoperative OR-Stretch Microbreaks: A pre-implementation study on two break scheduling strategies
Norasi, Hamid , Kim, Joseph , Zoaktafi, Mojgan , Hallbeck, M Susan, Kim, Joseph Y , Hallbeck, M Susar

Mayo Clinic

WORK: A Journal of Prevention, Assessment & Rehabilitation | July 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10519815261467018 | PMID 42415533 Get It

Background Surgeons face elevated risks of musculoskeletal disorders due to prolonged operating times, awkward postures, and repetitive tasks, which can impair performance and well-being. Microbreaks have emerged as a potential ergonomic intervention to reduce discomfort and fatigue during surgery. Objective The main goal of this study was to investigate and compare the intraoperative usability and effectiveness of two break scheduling strategies using the OR-Stretch TM Web-App. Furthermore, surgeons’ feedback on the primary barriers to implementation of the OR-Stretch Web-App was recorded. Methods This study used a randomized, within-subjects crossover design. Fourteen surgeons (eight females) performed three surgical procedures with the following microbreak schedules; (1) microbreaks every 30 min with an optional ten-minute snooze (Break-30), (2) microbreaks every 60 min with an optional ten-minute snooze (Break-60), or (3) no microbreaks (Baseline). Outcomes were measured using self-reported subjective surveys (e.g., discomfort, fatigue, workload, and usability). Results Surgeons found both Break-30 and Break-60 conditions aided physical performance, mental focus, body pain/discomfort, and level of fatigue (self-reported improvement between 28.6% and 78.6%). No significant differences were observed in surgeons’ subjective evaluations of the Break-30 and Break-60 conditions; however, the data suggest that Break-60 is preferable to the Break-30 condition. Conclusions This study provides evidence supporting the OR-Stretch Web-App as a potential surgical ergonomic intervention. However, enhancing the Web-App's user-friendliness and developing strategies to synchronize microbreaks with appropriate times during surgeries, to avoid disrupting the surgical workflow, are critical areas for future studies.
Patient-Centered Approach to Surgical Prevention of Ovarian Cancer
Lu, Karen H., Chisholm, Gary B. , Peterson, C., Roche, Kara Long , Bakkum-Gamez, Jamie, Feltmate, Colleen, Kim, Sarah, Hagemann, Andrea R. , Carter, Jeanne , Hickey, Martha, Crase, Jamie , Gavin, K, Polinsky, Deborah , D'Andrea, AD, Lu, Karen H. , Norquist, Barbara M. , Bakkum‐Gamez, Jamie N. , Romero, Iris L. , Feltmate, Colleen M. , Levine, Douglas A. , Hickey, Martha , Gavin, Kathleen , D’Andrea, Alan D. , Nebgen, Denise R. , Swisher, Elizabeth M.

Mayo Clinic

JAMA Network Open | July 7, 2026 | Volume: 9 | Issue: 7 | Pages: e2622026

10.1001/jamanetworkopen.2026.22026 | PMID 42412428 Get It

Importance Risk-reducing salpingo-oophorectomy (RRSO) is an effective option to prevent ovarian cancer in high-risk individuals, but adverse effects from premature menopause are a barrier to uptake. Interval salpingectomy with delayed oophorectomy (ISDO) may be an effective alternative. Objective To evaluate the association of ISDO vs RRSO and sexual function and menopausal symptoms. Design, Setting, and Participants This prospective, multicenter, nonrandomized (patient preference) clinical trial was performed among Women Choosing Surgical Prevention participants with a pathogenic or likely pathogenic germline variant conferring an increased risk for ovarian cancer. Patients from 9 US centers were enrolled from June 2, 2016, to October 28, 2020; chose ISDO or RRSO; and were followed up for 24 months. The analysis was performed on November 13, 2024. Interventions Participant-selected RRSO or ISDO. Main Outcomes and Measures Changes in sexual function and menopausal symptoms from baseline to 6, 12, and 24 months. Inverse probability weighting was applied to achieve covariate balance across groups. Results The analytic sample included 334 female participants (mean [95% CI] age at consent, 39.2 [38.7-.9.7] years) who underwent RRSO (n = 165) or ISDO (n = 169) and completed 6-month questionnaires. Significantly more participants experienced clinically meaningful worsening of sexual function at 6 months compared with baseline after RRSO vs ISDO (33.1% [39 of 118] vs 16.8% [17 of 101], respectively; odds ratio, 2.00 [95% CI, 1.20-3.35]) and at 12 months (39.2% [38 of 97] vs 18.3% [17 of 93], respectively; odds ratio, 1.69 [95% CI, 1.09-2.63]). This finding was no longer significant at 24 months. When restricted to the RRSO group who took hormone replacement therapy, there was no significant worsening of total sexual function scores or menopausal symptoms compared with baseline. No interval ovarian cancers were reported. Conclusions and Relevance This nonrandomized clinical trial comparing RRSO with ISDO found that ISDO was less likely to impair sexual function, which addresses an important barrier to surgical prevention in high-risk patients in premenopause. After RRSO, use of hormone replacement therapy mitigated menopausal symptoms and prevented decline in sexual function. More information is needed about the safety of ISDO. Trial Registration ClinicalTrials.gov Identifier: NCT02760849
Caregiver Reports of Lucid Episodes in Alzheimer’s Dementia and Lewy Body Dementias
Bangerter, Lauren R. , Kim, Kyungmin , Liu, Yin, Radford, Jonathan Graff, Liu, Yin, Lapid, Maria I. , Griffin, Joan M. , Kim, Kyungmin

Mayo Clinic

Journal of Geriatric Psychiatry and Neurology | July 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/08919887261464594 | PMID 42387273 Get It

Purpose of Research Lucidity is the transient recovery of abilities and communication that were seemingly lost among people living with dementia (PLWD). This study describes lucid episodes reported by Alzheimer’s dementia (AD) and Lewy Body Dementias (LBD) caregivers. We analyzed survey data from 212 current AD ( n = 191) and LBD caregivers who reported the frequency, duration, and characteristics of 653 lucid episodes witnessed in the past month. Major Findings Most AD caregivers (67%) and LBD caregivers (81%) witnessed a lucid episode within the past month. LBD caregivers reported lucid episodes with greater changes in awareness and communication, compared to AD caregivers. LBD caregivers reported longer lucid episodes and that the PLWD knew about their change in lucidity, compared to AD caregivers. Conclusions Findings suggest that differences in lucid episode intensity, timing, and meta-awareness between AD and LBD are possible and may inform care strategies for PLWD.
Toward autonomous robotic-assisted and microrobotic surgery
Yang, Sungyun , Kang, Byung Ha , Min, Hyeongho , Wachs, Juan , Alambeigi, Farshid , Desai, Jaydev P. , Yaeger, Kurt , Anderson, Katherine, Kuntz, Alan , Alterovitz, Ron , Webster, Robert J. , Hata, Nobuhiko , Reisenauer, Janani , Clinch, McKenna, Abramson, Alex , Wu, Jie Ying , Ranzani, Tommaso , Kim, Peter C., Huang, Alex S. , Zhang, Hao F. , Riviere, Cameron N. , Henderson, Eric R. , Yip, Michael C. , Dong, Xiaoguang , Wollin, Daniel , Mair, Lamar O. , Karpelson, Michael , Wood, Robert J. , Cohen, Itai , Strano, Michael S. , Wachs, Juan P , Dupont, Pierre E , Yaeger, Kurt , Anderson, Katherine , Kuntz, Alan , Alterovitz, Ron , Webster, Robert J , Hata, Nobuhiko , Reisenauer, Janani S , Clinch, McKenna , Abramson, Alex , Wu, Jie Ying , Ranzani, Tommaso , Sun, Cheng , Zhang, Hao F , Riviere, Cameron N , Henderson, Eric R , Yip, Michael , Dong, Xiaoguang , Wollin, Daniel A , Gracias, David H , Mair, Lamar O , Karpelson, Michael , Wood, Robert J , Cohen, Itai , Strano, Michael S

Mayo Clinic

Science Advances | July 1, 2026 | Volume: 12 | Issue: 27 | Pages: No page available

10.1126/sciadv.aec4197 | PMID 42384805 Get It

Autonomous robotic-assisted surgery (RAS) has emerged as a promising objective in biomedical technology, further enhanced by miniaturization toward microrobotic-assisted surgery (μ-RAS). This reduction in scale promises minimally invasive, partially or fully automated surgical procedures, with the potential to reduce patient recovery times, lower medical costs, and enable previously unavailable procedural options. This perspective highlights the specific advances in RAS that potentially map to the microscale (μ-RAS), organized across five surgical domains: endovascular, endoluminal, laparoscopic, ophthalmic, and orthopedic. We examine both clinical demands and technological advances in surgical robotics and identify the key innovations required for progress across these surgical fields. Our contribution is distinct in combining the perspectives of both surgical experts and bioengineering innovators, outlining a roadmap for the advancement and eventual integration of autonomous RAS and μ-RAS into mainstream surgical practice.
Opportunities for Human Lung Tissue-Based Studies in Fibrotic ILD Research
Kim, John S, Podolanczuk, Anna, Limper, Andrew H. , Hariri, Lida P. , Richeldi, L., Rosas, Iván O. , Jenkins, G, Luo, Fengming, Roman, Jesse , Sime, Patricia J. , Kaminski, N, Martinez, Fernando J, Noth, Imre , Hariri, Lida P , Limper, Andrew H , Sturek, Jeffrey M , Podolanczuk, Anna J. , Hannan, Riley T. , Richeldi, Luca , Luo, Fengming , Tomassetti, Sara , Thannickal, Victor J. , Kropski, Jonathan A , Kaminski, Naftali

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajrccm/aamag346 | PMID 42384176 Get It

A Randomized Phase II Study of Combination Atezolizumab and Varlilumab (CDX-1127) with or without Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer
Heumann, Thatcher , Lu, Jiayun , Wang, Hao , Phelps, Mitch A. , Zhu, Qingfeng , Anders, Robert A. , Mitchell, Sarah , Leatherman, James M. , Abbott, Nicole , Kim, Kyeongmin , Imhof, Teresa , Xie, Zhiliang , Partey, Alexandra , Kunk, Paul R. , Iyer, Renuka , Fonkoua, Lionel Aurelien Kankeu , Kalyan, Aparna , Gbolahan, Olumide B., Javle, Milind , Davis, S. Lindsey , Spencer, Kristen , Azad, Nilofer S. , Heumann, Thatcher Ross , Phelps, Mitch , Anders, Robert , Leatherman, James , Li, Daneng , Kunk, Paul Raymond , Iyer, Renuka , Dayyani, Farshid , Fonkoua, Lionel Aurelien A Kankeu , Kalyan, Aparna , Gbolahan, Olumide B , Javle, Milind M , Davis, S Lindsey , Florou, Vaia , Spencer, Kristen , Sharon, Elad , Yarchoan, Mark , Lesinski, Gregory B , Azad, Nilofer , Wang, Hao , Mitchell, Sarah , Li, Daneng , Dayyani, Farshid , Sharon, Elad , Yarchoan, Mark

Mayo Clinic

Clinical Cancer Research | June 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF12

10.1158/1078-0432.ccr-25-4893 | PMID 42377085 Get It

Abstract Purpose: The addition of MEK inhibition (MEKi) to programmed cell death ligand 1 (PD-L1) blockade improves progression-free survival (PFS) in patients with advanced biliary tract cancer. Although MEK inhibitors may increase tumor cell immunogenicity, they can impair T-cell priming/effector function, limiting combination efficacy. We hypothesized that the addition of a CD27 agonist could restore T-cell function and enhance antitumor immunity in this combination. Patients and Methods: We conducted a randomized, phase II trial evaluating atezolizumab (840 mg, intravenously, days 1 and 15) in combination with the CD27 costimulatory monoclonal antibody [CDX-1127/varlilumab (3 mg/kg, intravenously, days 1 and 15)], with/without the addition of an MEK inhibitor [cobimetinib (60 mg, orally, daily, days 1–21, off days 22–28)] in unresectable biliary tract cancer following at least one metastatic therapy. Overall response rate (ORR) and PFS were coprimary endpoints. Treatment-related changes in CD8+ tumor-infiltrating lymphocytes (TIL) were the primary correlative outcomes. Results: The trial was closed early following interim preplanned ORR analysis. At closure, 57 patients had been enrolled [n = 29 in the cobimetinib + atezolizumab + varlilumab (CAV) arm; n = 28 in the atezolizumab + varlilumab (AV) arm]. A majority (67%) had intrahepatic cholangiocarcinoma, and 32% were immunotherapy experienced. Both regimens were well tolerated without new safety signals. Objective responses were rare [0% (CAV); 3.8% (AV)]. The median PFS (mPFS) was 2.40 (CAV) and 1.84 (AV) months [hazard ratio (HR), 0.67; 95% confidence interval (CI), 0.38–1.18]. Among immunotherapy-experienced patients, the mPFS was 3.62 (CAV) and 1.84 (AV) months (HR, 0.54; 95% CI, 0.18–1.62). Treatment with CAV increased intratumoral CD8+ T-cell density compared with treatment with AV. Conclusions: The combinations of atezolizumab and varlilumab with/without cobimetinib were safe, but neither meaningfully improved outcomes in biliary tract cancer treated in the later lines. Correlative tissue studies validated preclinical work that MEKi increases CD8+ TILs.